ClinicalTrials.gg
Not yet recruitingNCT07828223KT-CANOPYUpdated Sep 18, 2026

Cardiac Improvement by Eplerenone Among Patients Under Cyclosporine or Tacrolimus for Kidney Transplantation.

A Phase 3 interventional study of Eplerenone in Kidney Transplantation, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Central Hospital, Nancy, France · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this research is to evaluate the effect, for 36 weeks, of eplerenone on abnormalities observed on cardiac ultrasound in patients with kidney transplantation for at least one year, under cyclosporine or tacrolimus. The intervention group will receive the usual standard treatment coupled with eplerenone for 36 weeks from randomization, while the control group will only receive the standard treatment. The main hypothesis is that anticalcineurins (cyclosporin or tacrolimus) lead to activation of the MR of vascular smooth muscle cells, vasoconstriction and vascular inflammation, which contributes to the persistence or recurrence of heart abnormalities in these patients after the initial post-transplant phase. The administration of eplerenone could antagonize this hyperactivation, reduce the cardiovascular effects of anticalcineurins and thus ultimately improve the cardiovascular prognosis of transplant patients.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • Eplérénone
  • Anticalcineurines
  • Kidney transplantation
  • cardiovascular
03

In context

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 799 studies on the registry; 187 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female with 18 years old or older.
  • Transplant patient for at least one year.
  • Patient on long-term cyclosporine or tacrolimus.
  • Patient whose clinical situation has been stable for at least 3 months, without major treatment modification and without an episode of acute rejection.
  • Patient with renal function with a (glomerular filtration rate) greater than or equal to 40 ml/min/1.73m2.
  • Patient with systolic blood pressure greater than or equal to 110 mmHg, with or without antihypertensive treatment.
  • Patient with the following echocardiographic abnormalities at baseline : an left ventricular mass > to 88 g/m2 in females or > to 102 g/m2 in males and/or left atrial volume > 34 ml/m2.

Exclusion criteria

Exclusion Criteria:

  • Kidney transplant recipient more than 5 years post-transplantation.
  • Patient with permanent atrial fibrillation.
  • Patient with valvular heart disease (grade ≥ 3).
  • Patient considered to be at very high risk of mortality within the next year.
  • Patient with documented serum potassium ≥ 5.0 mmol/L within the previous month or receiving long-term potassium-binding resin therapy.
  • Patient with documented serum bicarbonate \< 20 mmol/L within the previous month, with or without bicarbonate supplementation.
  • Patient receiving treatment with a mineralocorticoid receptor antagonist or having a formal indication for such treatment.
  • Patient receiving another potassium-sparing diuretic.
  • Patient receiving combined treatment with an ACE inhibitor and an angiotensin receptor blocker (each agent being permitted individually).
  • Patient receiving digoxin therapy.
  • (LVEF) \< 40% on the baseline echocardiographic assessment.
  • Planned closure of an existing arteriovenous fistula within the following year.
  • Known or allergy to eplerenone or any of its .
  • Patient with severe hepatic impairment ( class C).
  • Patient currently receiving treatment with a strong inhibitor (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin, or nefazodone).
  • Patient with known galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndrome.
  • Patient with a to Kayexalate®: history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, or concomitant treatment with sorbitol-containing laxatives.
  • Woman of not using an effective method of or planning to become pregnant within the next 12 months.
  • Patient participating in another interventional clinical study involving modifications to therapeutic management.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Intervention group (under Eplerenone):

    Standard treatment according to usual care, combined with eplerenone for 36 weeks. Start of treatment with eplerenone at the initial dose of 25 mg/day, then adjusted according to clinical and biological tolerance: 12.5 mg/day (i.e., 25 mg/48h), 25 mg/day, and 50 mg/day.

    Drug: Eplerenone

  • No intervention
    Controle group (without eplerenone):

    Standard treatment according to usual care, it can or cannot include a renin-angiotensin system blocker, left to the discretion of the physician in charge of the patient.

Interventions

  • The intervention group will receive standard treatment according to usual care, coupled with eplerenone for 36 weeks from randomization. Start of treatment with eplerenone at the initial dose of 25 mg/day, then adjusted according to clinical and biological tolerance: 12.5 mg/day (i.e., 25 mg/48h), 25 mg/day, and 50 mg/day.

06

What researchers measure

Primary outcomes

  1. Hierarchical composite endpoint (win ratio) : 1/ Death or hospitalization for heart failure or acute coronary syndrome, 2/ Variation in indexed left ventricular mass, 3/Variation in indexed left atrial volume.

    Time frame: at 36 weeks

Secondary outcomes

  1. Evolution of Nt-ProBNP concentration

    Time frame: randomization, at 12 and 36 weeks

  2. Evolution of collagen biomarkers (PICP )

    Time frame: at 36 weeks

  3. Evolution of Biological markers of endothelial dysfunction (endothelin)

    Time frame: at 36 weeks

  4. The occurrence of hyperkalaemia

    hyperkalaemia between 5 - 5.49; 5.5 - 6; \>6mmol/L

    Time frame: at 36 weeks

  5. Proportion of creatinine increase > 50%

    Assessment of the proportion of acute kidney injury (AKI), defined as a \>50% increase in serum creatinine from baseline.

    Time frame: at 36 weeks

  6. Evolution of parameters of systolic function (LVEF, strain)

    Time frame: at 36 weeks

  7. Evolution of parameters of remodeling (left ventricular volume)

    Time frame: at 36 weeks

  8. Evolution of parameters of filling pressures (E/e')

    Time frame: at 36 weeks

  9. Evolution of peripheral systolic blood pressure (mmHg)

    Time frame: at 36 weeks

  10. Evolution of peripheral diastolic blood pressure (mmHg)

    Time frame: at 36 weeks

  11. Evolution of peripheral pulse pressure (mmHg)

    Time frame: at 36 weeks

  12. Evolution of Graft function assessed with serum creatinine (micromol/L)

    Graft function assessed with serum creatinine with estimation of glomerular filtration rate according to the CKD-EPI formula. The percentage of patients with GFR ≥ 90, 60-89, 45-59, 30-44, 15-29, \<15ml/min/1.73m2 will also be assessed.

    Time frame: at 36 weeks

  13. Evolution of proteinuria (mg/g)

    Proteinuria measured by the proteinuria/creatininuria ratio. The percentage of patients with proteinuria/creatininuria ratio \<500; 500-1000, 1000-2000, 2000-3000, \>3000mg/g will also be assessed.

    Time frame: at 36 weeks

  14. Evolution of parameters of remodeling (left atrial volumes)

    Time frame: at 36 weeks

  15. Evolution of collagen biomarkers ( PIIINP)

    Time frame: at 36 weeks

  16. Evolution of Biological markers of endothelial dysfunction ( soluble endothelium selectin)

    Time frame: at 36 weeks

  17. Evolution of Biological markers of endothelial dysfunction (von Willebrand factor)

    Time frame: at 36 weeks

  18. Evolution of parameters of filling pressures (E-wave deceleration time).

    Time frame: at 36 weeks

  19. Evolution of parameters of filling pressures (Systolic Pulmonary Artery Pressure (PAPs)).

    Time frame: at 36 weeks

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2027; primary completion for Dec 2030, 46 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 18, 2026
StartEst.
Feb 2027
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07828223
Responsible party
Pr. Nicolas GIRERD (Study chair, Central Hospital, Nancy, France) — Principal investigator
First posted
Sep 18, 2026
Start date
Feb 2027 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 18, 2026

Study contacts

Nesrine BAILI, MD
Contact
N.BAILI@chru-nancy.fr
+33 03 83 85 85 85
Adrien FLAHAULT, Md PhD
Contact
A.FLAHAULT@chru-nancy.fr
Nicolas GIRERD, Md PhD
study chair · CHRU NANCY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eplerenone

Start the discussion